Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult...
- FDA accelerated review denial is a blow to Spectrum’s poziotinib
- New drugs and therapeutic options help the immune system fight cancer
- Roche’s Tecentriq threatens BMS’ Opdivo in small cell lung cancer market
- The challenges of using stem cells in neurology
- Another BACE inhibitor fails in phase III trials
Quick and Flexible Elemental Screening with Omnian
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
April’s top news stories
Chinese clinical-stage biopharmaceutical company I-Mab Biopharma and German biotech company MorphoSys have begun the first dosed Phase III clinical study to assess investigational human CD38 antibody TJ202/MOR202 in combination with lenalidomide in patients suffering from relapsed or refractory multiple myeloma; and A small clinical trial by researchers at the University of Edinburgh in the UK has showed that cilostazol and isosorbide mononitrate could prevent recurrence of stroke and vascular dementia. Drugdevelopment-technology.com wraps up the key headlines from April 2019.
Detecting the Presence of Trace Polymorphs and Impurities
In the pharmaceutical industry, the detection of polymorph traces is one of the most important applications of powder x-ray diffraction (PXRD).
Eligen® Technology Mechanism of Action
Emisphere's Eligen® Technology binds a delivery agent with a therapeutic compound without alternation. This process occurs when both agent and compound are in close proximity.
Nerlynx (neratinib) for the Treatment of Breast Cancer
Nerlynx™ (neratinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with early stage HER2-overexpressed or amplified breast cancer.
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
Clinically Relevant Mesenchymal Stem Cell Populations For Research
Renovos offers unique bone marrow mesenchymal stem cells (MSC), which have been isolated from patients with osteoarthritis for research purposes.
Stem Cells Sourced from Healthy and Diseased Donors
Caltag Medsystems specialises in procuring haematopoietic cells collected from healthy and diseased donors. Its suppliers are able to isolate and purify haematopoietic cells from a variety of tissues, including peripheral blood, mobilised peripheral blood, bone marrow and cord blood.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.